Could a lower drug dose make stem cell transplants safer for blood cancer patients?
NCT ID NCT03983850
First seen Nov 01, 2025 · Last updated Apr 29, 2026 · Updated 28 times
Summary
This study looks at whether giving a lower dose of the drug cyclophosphamide after a stem cell transplant can help control blood cancers like leukemia and lymphoma with fewer side effects. About 105 people aged 15 to 65 with high-risk blood cancers will receive a transplant from a relative, followed by the lower drug dose. The goal is to make the transplant safer and more successful.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMATOLOGIC NEOPLASMS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.